1. Home
  2. CTW vs ARMP Comparison

CTW vs ARMP Comparison

Compare CTW & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTW

CTW Cayman Class A Ordinary Shares

N/A

Current Price

$1.81

Market Cap

132.9M

Sector

Technology

ML Signal

N/A

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

N/A

Current Price

$5.62

Market Cap

125.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTW
ARMP
Founded
2013
N/A
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.9M
125.7M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
CTW
ARMP
Price
$1.81
$5.62
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
52.8K
55.3K
Earning Date
11-17-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$90,370,793.00
$5,054,000.00
Revenue This Year
N/A
$4.48
Revenue Next Year
N/A
N/A
P/E Ratio
$29.93
N/A
Revenue Growth
32.07
N/A
52 Week Low
$1.71
$0.90
52 Week High
$4.88
$16.34

Technical Indicators

Market Signals
Indicator
CTW
ARMP
Relative Strength Index (RSI) N/A 47.36
Support Level N/A $5.67
Resistance Level N/A $6.39
Average True Range (ATR) 0.00 0.59
MACD 0.00 -0.12
Stochastic Oscillator 0.00 24.42

Price Performance

Historical Comparison
CTW
ARMP

About CTW CTW Cayman Class A Ordinary Shares

CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: